OncLive TV

David P. Carbone, MD, PhD, discusses the impact of immunotherapy on lung cancer.

Hope S. Rugo, MD, discusses recent updates with immunotherapy in triple negative breast cancer.

Panayiotis S. Savvides, MD, discusses the utility of immunotherapy in lung cancer.

Jennifer Litton, MD, discusses the findings from the overall survival analysis of the EMBRACA trial, the implications of these data, and the future utility of talazoparib in this space.

Sonali M. Smith, MD, discusses ongoing research in relapsed/refractory mantle cell lymphoma.

Anastasios (Tassos) Dimou, MD, discusses emerging treatment options in BRAF-positive lung cancer.

Manish Kohli, MD, discusses the use of enzalutamide (Xtandi) and apalutamide (Erleada) in patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Manoj K. Jain, MD, discusses diagnostic tracers in prostate cancer.

Anastasios (Tassos) Dimou, MD, discusses emerging treatment options in BRAF-positive lung cancer.

Sonali M. Smith, MD, discusses ongoing research in relapsed/refractory mantle cell lymphoma.

Andrew Yee, MD, discusses trials evaluating treatment for patients with lenalidomide-refractory multiple myeloma.

Jessica Donington, MD, MSCR, discusses the role of neoadjuvant immunotherapy in patients with stage II non–small cell lung cancer.

Michael Wang, MD, discusses research trends in mantle cell lymphoma (MCL).

Phillip J. Koo, MD, discusses the need for next-generation imaging in prostate cancer.

Carlos E. Vargas, MD, discusses research with proton therapy in prostate cancer.

Che-Kai Tsao, MD, shares strategies to improve outcomes in renal cell carcinoma.

Betsy O'Donnell, MD, discusses the utility of up-front triplet regimens in multiple myeloma.

Rogerio C. Lilenbaum, MD, discusses the rise of immunotherapy in non–small cell lung cancer.

Jessica Donington, MD, MSCR, discusses the role of neoadjuvant immunotherapy in patients with stage II non–small cell lung cancer. 

Jamie E. Chaft, MD, discusses immune-related adverse effects in non–small cell lung cancer.

Rogerio C. Lilenbaum, MD, discusses the rise of immunotherapy in non–small cell lung cancer. 

Gilberto De Lima Lopes, MD, discusses the FDA approval of nivolumab (Opdivo) and ipilimumab (Yervoy) in non–small cell lung cancer (NSCLC).

Naval G. Daver, MD, discusses anticipated breakthroughs in acute myeloid leukemia (AML).

David F. Penson, MD, MPH, MMHC, discusses ongoing research in prostate cancer.

William L. Dahut, MD, discusses the future of genetic screening in prostate cancer.

Warner K. Huh, MD, discusses some of the key challenges faced in the management of gynecologic cancers in light of the COVID-19 crisis, shares some of the resources provided by the SGO COVID-19 task force, and projects what is needed to quell the pandemic, which he refers to as version of the Great Depression.

Jean Wright, MD, discusses radiation considerations in breast cancer.

Ronald B. Natale, MD, discusses the evolution of immunotherapy in advanced non–small cell lung cancer.

Andrew D. Zelenetz, MD, PhD, discusses progress made in mantle cell lymphoma treatment.